quinidine has been researched along with 4-o-methyl-12-o-tetradecanoylphorbol 13-acetate in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Berkovic, SF; Dibbens, LM; Dlugos, DJ; Gazina, EV; Goldstein, DB; Heron, SE; Li, M; Milligan, CJ; Nair, U; Petrou, S; Petrovski, S; Reid, CA; Scheffer, IE; Trager, C; Venkat, A; Younkin, DP | 1 |
1 other study(ies) available for quinidine and 4-o-methyl-12-o-tetradecanoylphorbol 13-acetate
Article | Year |
---|---|
KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Electric Stimulation; Humans; Male; Membrane Potentials; Mice; Mice, Inbred C57BL; Microinjections; Mutation; Nerve Tissue Proteins; Oocytes; Patch-Clamp Techniques; Potassium Channels; Potassium Channels, Sodium-Activated; Quinidine; Tetradecanoylphorbol Acetate; Time Factors; Voltage-Gated Sodium Channel Blockers; Xenopus laevis | 2014 |